ABSTRACT
In this chapter we describe how the decision-making criteria for determining whether to advance a molecule from Phase 2 to Phase 3 as well as the size of the Phase 2 study impacts the efficiency of drug development. To do this we specify a simple model of drug discovery and use it to evaluate the properties of Phase 2 studies and their associated decision rules.
